FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Thursday

 

Ways to Pay for Your Expensive MS Drugs































Image Source: REINAWEINER


By Kim Dolce


The biggest news during March of this year was the FDA approval of Ocrevus, the first disease-modifying drug found effective in treating both relapsing-remitting MS (RRMS) and primary-progressive MS (PPMS). The news drew many responses from our readers, many of whom expressed concern about the cost and their ability to get access to this new and extremely expensive Tier 5 drug.

It troubled me to see that many MS patients are still not aware of patient assistance programs as a major resource that can help us pay for our disease-modifying drugs. So here’s a rundown of financial resources, most of which you can easily access either by phone or website:

Ocrevus

Ocrevus is manufactured by Genentech, a pharma company owned by the Roche group.  You can find its patient assistance program info at the Genentech site: www.genentech-access.com. Click on Patient Assistance Tool and then answer the yes or no questions about your insurance status. You can also call (866) 422-2377.

If you receive government insurance such as Medicare or Medicaid, you’ll be referred to an independent co-pay assistance foundation. Every drug company has a patient assistance program, and most have referral lists to charity foundations such as NORD and Patient Access Network. If you don’t want to research this yourself, you can ask your medical team to find the information for you.


Avonex

Avonex is manufactured by Biogen. To access its patient assistance program, call 1-800-456-2255.

Aubagio

Aubagio is made by Sanofi-Genzyme. For co-pay assistance, the website advises you to talk to your healthcare provider for instructions. It emphasizes co-pay assistance for commercial insurance holders only. The only phone number published on the website is for the One-to-One program, a 24/7 on-call nurses program for those with drug questions at 1‑855‑676‑6326.

*Although the website doesn’t mention charity foundation support for Medicare/Medicaid patients, making an inquiry about such options is recommended. If they don’t provide the option, see a list at the bottom of this article for charitable foundations.


Copaxone

Copaxone is made by Teva. Call Shared Solutions, their support program at 1-800-887-8100.

Betaseron

Betaseron is manufactured by Bayer. Contact their patient assistance program at 1-800-788-1467, press option 2, and talk with a Coverage Specialist to learn more.

Extavia

Extavia similar to Betaseron, is manufactured by Novartis. Call its patient assistance program at: 1-866- 398-2842.

Gilenya

Gilenya is made by Novartis. The website claims that most eligible patients pay a $0 co-pay. www.gilenya.com/c/ms-pill/co-pay. The application process starts when you sign up to take the drug. The Novartis care team will contact you with an evaluation.

Glatopa Glatopa similar to Copaxone, is made by Sandoz, Inc. Contact patient assistance at 1-855-452-8672.

Plegridy
Plegridy is made by Biogen. Call 1-800-456-2255.

Rebif

Rebif is made by EMD Serono. For MS Lifelines assistance program call: 1-877-447-3243.

Tecfidera and Tysabri

Tecfidera and Tyesabri are manufactured by Biogen. Call 1-800-456-2255.

Zinbryta

Zinbryta is made by Biogen and Abbvie. For co-pay assistance, call 1-800-456-2255.

You can find similar assistance for expensive symptom medications, too. For example, Tier 4 medications such as Ampyra, manufactured by Biogen, can be prohibitively expensive as well. If you’re having trouble paying for Ampyra, call the above number for Tecfidera and Avonex to apply for co-pay assistance. If your drug plan’s formulary is no longer covering an expensive symptom medication and the alternative is not going to be an effective equivalent, don’t hesitate to call any of the drug companies for solutions. In many cases, you don’t have to go without an effective drug just because your insurance refuses to pay for it.


Following is a list of charity foundations that help chronically ill patients cover their drug costs.


The Patient Access Network Foundation   www.patientaccessnetwork.org


Caring Voice Coalition  http://caringvoice.org/


The Chronic Disease Fund   www.cdfund.org


The HealthWell Foundation   www.healthwellfoundation.org


Patient Services Incorporated  www.uneedpsi.org


NORD  https://rarediseases.org/for-patients-and-families/help-access-medications/patient-assistance-programs/



Story Source: The above story is based on materials provided by MULTIPLESCLEROSIS.NET
Note: Materials may be edited for content and length

Labels: , , , , , , , , , ,



Go to Newer News Go to Older News